NCT06769412View on ClinicalTrials.gov

A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US)

RecruitingOBSERVATIONAL

Enrollment

550,000

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

August 15, 2025

Study Completion Date

September 1, 2025

Conditions

Retinal Vasculitis

Interventions

DRUG

aflibercept 2 mg

No study-specific investigations for this descriptive observational study

Trial Locations (1)

10591

RECRUITING

Regeneron Research Site, Tarrytown

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT06769412 - A Real-World Evidence Study for the Incidence of Retinal Vasculitis (RV) Among Adult Patients Receiving Aflibercept 2 mg in the United States (US) | Biotech Hunter | Biotech Hunter